Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of Sporanox and Lozanoc has not been compared in patients requiring
anti-fungal prophylaxis or therapy. The present study is designed to compare the
pharmacokinetics of Sporanox and Lozanoc in patients requiring primary prophylaxis. The
3-week exposure to each formulation is designed to allow for all participants to reach
steady-state for each drug, as the time to steady-state can vary.